Cargando…

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib

The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration’s (FDA) approval of poly-ADP ribose polymerase (PARP) inhibitors (PARPi). One of the deadliest cancers that women experience, ovarian cancer, is most often diagnosed in advanced stages. Alth...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearre, Diana C, Tewari, Krishnansu S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223341/
https://www.ncbi.nlm.nih.gov/pubmed/30464492
http://dx.doi.org/10.2147/TCRM.S149248